CureMatch
×
  • Physicians
  • Patients
  • Employers
  • About Us
  • News
    • CureMatch News
    • Validation and Research
    • Events & Conferences
  • Contact
  • Login
Francis Giles, MD

Francis Giles, MD

DEPUTY DIRECTOR AND CHIEF OF THE DIVISION OF HEMATOLOGY/ONCOLOGY, NORTHWESTERN UNIVERSITY FEINBERG SCHOOL OF MEDICINE

A cancer specialist with more than two decades of experience, Dr. Francis Giles has led the development of novel drugs, immunotherapies, and other highly targeted approaches, including cancer-directed viruses, monoclonal antibodies, and molecularly directed agents.  Dr. Giles currently serves as Director of Developmental Therapeutics at the Robert H. Lurie Comprehensive Center of Northwestern University where he has also served as Deputy Director and as Chief of the Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine. He previously served as Deputy Director of the Cancer Therapy and Research Center at the University of Texas (UT) Health Science Center, San Antonio, and Chief of the Division of Hematology and Medical Oncology and Director of the Institute for Drug Development. His prior positions include serving as Chairman, Clinical Research Committee, and Professor in the Division of Cancer Medicine at the UT MD Anderson Cancer Center, Houston; and as a faculty member at the University of California, Los Angeles, and the University of North Carolina at Chapel Hill. He is the founder and Chairman of both the International Oncology Study Group and the Developmental Therapeutics Consortium. Dr. Giles has led the development of novel drugs, immunotherapies, and other highly targeted approaches, including cancer-directed viruses, monoclonal antibodies, and molecularly directed agents. He has served as principal investigator on numerous national and international First in Human, Phase I, II, and III clinical studies of many novel agents, and holds numerous patents and technology licenses.

logo

+1 (858) 284-0488

FAX: +1 (858) 430-5813

Quick Links

  • Physicians
  • About CureMatch
  • News and Latest Posts
    • CureMatch News
    • Validation and Case Studies
    • Events and Conferences
  • Contact Us
  • FAQ

Latest News and Results

  • Interview with Dr. Razelle Kurzrock of CureMatch: Why Patients Need Precision Cancer Medicine Apr 6

    In this dynamic interview, Chief Medical Advisor, Dr. Kurzrock, sits down with Michelle Morand, Co-Founder...

  • New Study Validates Payer/Physician Use of AI to Cut Wasteful Spending on High-Cost, Low-Value Cancer Drugs Mar 28

    The Research Consortium announced the release of a new study today that challenges common misconceptions...

  • CureMatch Names Life Sciences Executive David Szekeres as Board Director Feb 22

    CureMatch, Inc., a healthcare technology company that leverages artificial intelligence (AI) to power precision medicine...

© 2021 CureMatch, Inc. CureMatch is a registered trademark.
Terms of Use | Privacy Policy | HIPAA Notice

We’d like to send you a CureMatch Sample Analysis

 

Sample Analysis Download Form

  • This field is for validation purposes and should be left unchanged.

 

We value and respect your privacy and will not publish, share, or sell your contact information.

View Privacy Policy

Some pages of this website are intended for healthcare professionals

This webpage is strictly reserved for healthcare professionals. Please confirm that you are a healthcare professional.

Otherwise, you will be redirected to the institutional part of this website.

Thank you for your understanding.

I am a healthcare professionalI am not a healthcare professional

Get ready to utilize the latest genomics data in your practice

Rank the most promising systemic therapies for your patients

Do you need to filter out those therapies with poor outcomes

Sort through 4.5 million expertly curated combinations of drugs

Compute your own drug choices alongside CureMatch data